Preconditioning with interleukin‐1 beta and interferon‐gamma enhances the efficacy of human umbilical cord blood‐derived mesenchymal stem cells‐based therapy via enhancing prostaglandin E2 secretion and indoleamine 2,3‐dioxygenase activity in dextran sulfate sodium‐induced colitis

Yu, Yeonsil; Yoo, Sae Mi; Park, Hwan Hee; Baek, Song Yi; Kim, Yoon‐Jin; Lee, Seung‐Hee; Kim, Yu-Lee; Seo, Kangmoon; Kang, Kyung‐Sun

doi:10.1002/term.2930

Cited by 44 publications

(32 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, according the ratios of IL-1β to IL-10 and IL-1β to IL-6 ratios, IL-1βexpression was signi cantly higher than that of IL-10 and IL-6 in the intestine following hypothermia, and it returned to around normal expression levels following rewarming for 2 h. Thus, it is speculated that IL-1β is a hypothermia speci c in ammatory factor that could be used to assess the severity of hypothermia. IL-1β is a common in ammatory factor that is produced by monocytes, endothelial cells, broblasts and other types of cells in response to infection [30,31]. IL-1β could stimulate the production of colonystimulating factor, and platelet-derived growth factor and also could induce T cells to produce IL-2, which serves an important role in immune response and tissue repair.…”

Section: Discussionmentioning

confidence: 99%

Rewarming rats at 37˚C rescues hypothermia with significant changes in IL-1β levels in the intestinal tissue and blood

Xiong

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Hypothermia secondary to accidental exposure is becoming increasingly prevalent in the general population; however, the mechanisms and early treatments of hypothermia require additional study. Methods A hypothermia-rewarming SD rat model was established by immersing rats in 15˚C seawater for 5h and then rewarming at 37˚C for 2, 6 and 12 h. The rats were randomly divided into a normal control group (group C), hypothermia group (group H) and rewarming group (group R). The changes in the levels of inflammatory factors and pathophysiology of the intestinal tissues of rats were assessed. The blood was collected in test tubes, and the levels of cytokines in the separated plasma were detected using ELISA. The intestinal tissue was ground and lysed, and protein expression profiles of 67 inflammatory factors were measured using a protein chip. These samples were further subjected to reverse transcription-quantitative (RT-q)PCR analysis and tissue section staining. Results The temperature of the abdomen and the physiological state of the rats was significantly altered during immersion in the hypothermic seawater, and returned to normal after rewarming. The protein chip showed that inflammatory factors, including IL-1β, IL-10 and IL-6, were differentially expressed in the intestine. Using ELISA, it was shown that IL-1β, IL-6 and IL-10 levels were also upregulated in the plasma. Comparing the ratios of IL-1β to IL-6 and IL-1β to IL-10, IL-1β was found to be significantly more upregulated compared with IL-10 and IL-6 in the intestine during hypothermia. The immunohistochemical staining of IL-1β showed that IL-1βexpression first increased then decreased during the rewarming period, and similar results were obtained based on RT-qPCR analysis. Conclusion Rewarming at 37˚C may be a suitable method for early treatment of hypothermia, and IL-1β may serve as a potential biomarker for assessing the severity of hypothermia.

show abstract

Section: Discussionmentioning

confidence: 99%

Rewarming rats at 37˚C rescues hypothermia with significant changes in IL-1β levels in the intestinal tissue and blood

Xiong

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…[74][75][76] When activated by inflammatory factors, MSCs become potently immunosuppressive, secreting soluble mediators (e.g., NO and prostaglandin E2) to decrease excessive immune reactions. [76][77][78] They suppress T cell proliferation, B lymphocyte differentiation, and natural killer cell functions; also, they modulate macrophage phenotypes, disturb dendritic cell functions, [78][79][80][81] and decrease the secretion of proinflammatory cytokines. 73,74,76 Notably, the immunomodulation of MSCs is FIG.…”

Section: Immunomodulationmentioning

confidence: 99%

Mesenchymal Stem Cells for Chronic Wound Healing: Current Status of Preclinical and Clinical Studies

Huang

Gou

et al. 2020

Tissue Engineering Part B: Reviews

142

View full text Add to dashboard Cite

Healing skin wounds with anatomic and functional integrity, especially under chronic pathological conditions, remain an enormous challenge. Due to their outstanding regenerative potential, mesenchymal stem cells (MSCs) have been explored in many studies to determine the healing ability for difficult-to-treat diseases. In this article, we review current animal studies and clinical trials of MSC-based therapy for chronic wounds, and discuss major challenges that confront future clinical applications. We found that a wealth of animal studies have revealed the versatile roles and the benefits of MSCs for chronic wound healing. MSC treatment results in enhanced angiogenesis, facilitated reepithelialization, improved granulation, and accelerated wound closure. There are some evidences of the transdifferentiation of MSCs into skin cells. However, the healing effect of MSCs depends primarily on their paracrine actions, which alleviate the harsh microenvironment of chronic wounds and regulate local cellular responses. Consistent with the findings of preclinical studies, some clinical trials have shown improved wound healing after transplantation of MSCs in chronic wounds, mainly lower extremity ulcers, pressure sores, and radiation burns. However, there are some limitations in these clinical trials, especially a small number of patients and imperfect methodology. Therefore, to better define the safety and efficiency of MSC-based wound therapy, large-scale controlled multicenter trials are needed in the future. In addition, to build a robust pool of clinical evidence, standardized protocols, especially the cultivation and quality control of MSCs, are recommended. Altogether, based on current data, MSC-based therapy represents a promising treatment option for chronic wounds.

show abstract

“…This inhibitory effect is associated with a sharp downregulation of the surface expression of activated NK receptors NKp30, NKp44, and NKG2D. IDO and PGE2 also inhibit the differentiation of Th1 cells, promote the differentiation of Tregs, and increase the migration of CD4 + T cells [117,118]. IDO promotes the expansion of CD4 + FoxP3 + IL-10 + T regulatory cells and inhibits the proliferation of Th17 cells [119].…”

Section: Immunoregulation Of Mesenchymal Stem Cellsmentioning

confidence: 99%

Applications of Mesenchymal Stem Cells in Liver Fibrosis: Novel Strategies, Mechanisms, and Clinical Practice

Zhu

Hua

Ouyang

et al. 2021

Stem Cells International

View full text Add to dashboard Cite

Liver fibrosis is a common result of most chronic liver diseases, and advanced fibrosis often leads to cirrhosis. Currently, there is no effective treatment for liver cirrhosis except liver transplantation. Therefore, it is important to carry out antifibrosis treatment to reverse liver damage in the early stage of liver fibrosis. Mesenchymal stem cells (MSCs) are the most widely used stem cells in the field of regenerative medicine. The preclinical and clinical research results of MSCs in the treatment of liver fibrosis and cirrhosis show that MSC administration is a promising treatment for liver fibrosis and cirrhosis. MSCs reverse liver fibrosis and increase liver function mainly through differentiation into hepatocytes, immune regulation, secretion of cytokines and other nutritional factors, reduction of hepatocyte apoptosis, and promotion of hepatocyte regeneration. Recently, many studies provided a variety of new methods and strategies to improve the effect of MSCs in the treatment of liver fibrosis. In this review, we summarized the current effective methods and strategies and their potential mechanisms of MSCs in the treatment of liver fibrosis, as well as the current research progress in clinical practice. We expect to achieve complete reversal of liver injury with MSC-based therapy in the future.

show abstract

Preconditioning with interleukin‐1 beta and interferon‐gamma enhances the efficacy of human umbilical cord blood‐derived mesenchymal stem cells‐based therapy via enhancing prostaglandin E2 secretion and indoleamine 2,3‐dioxygenase activity in dextran sulfate sodium‐induced colitis

Cited by 44 publications

References 40 publications

Rewarming rats at 37˚C rescues hypothermia with significant changes in IL-1β levels in the intestinal tissue and blood

Rewarming rats at 37˚C rescues hypothermia with significant changes in IL-1β levels in the intestinal tissue and blood

Mesenchymal Stem Cells for Chronic Wound Healing: Current Status of Preclinical and Clinical Studies

Applications of Mesenchymal Stem Cells in Liver Fibrosis: Novel Strategies, Mechanisms, and Clinical Practice

Contact Info

Product

Resources

About